Title : Microbial diversity drives metabolic alterations and disrupts functional pathways in acute myocardial infarction: Evidence from three distinct microbiotic compartments
Abstract:
Our study investigates the interplay between the microbiome and metabolome in acute myocardial infarction (AMI), focusing on the diagnostic potential of blood, gut, and oral microbiota and their metabolomic signatures. Blood, fecal, and saliva samples from AMI patients and healthy controls were analyzed using 16S rRNA sequencing and LC-MS metabolomics. The analysis revealed distinct patterns across the microbiomes and metabolomes of AMI patients. In the blood microbiome, while alpha and beta diversity showed no significant differences, specific bacterial taxa (e.g., Proteobacteria, Gammaproteobacteria, and Bacilli) and metabolites (e.g., UDP-L-Ara4O, Urotensin-related peptide, and 9-hydroxy octadecanoic acid) exhibited exceptional diagnostic potential (AUC: 0.99–1.00). Functional analysis identified upregulated glycerolipid metabolism and mTOR signaling pathways correlated with clinical markers of AMI. The gut microbiome demonstrated significant beta diversity differences between AMI patients and controls, with biomarkers such as Bifidobacterium and Prostaglandin J2 showing strong diagnostic potential (AUC: 0.92–0.99). Functional pathways, including arginine biosynthesis and serotonergic synapse pathways, were upregulated. In the oral microbiome, both alpha and beta diversity differed significantly, identifying Streptococcus, Rothia, and metabolites like 9(R)-HODE and 5,6-EET as potential biomarkers (AUC: 0.82–0.88). Functional analysis revealed upregulation in glucagon signaling and pyruvate metabolism pathways. This integrative analysis underscores the diagnostic potential of microbiome-metabolome profiles in AMI, providing valuable insights into biomarker-driven diagnostics and targeted therapeutic interventions.
